Zilico is the result of the desire to improve cancer diagnosis in partnership with some great scientific minds at Sheffield University.
Zilico was set up following a successful collaboration between the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, UK, to develop a more accurate means of diagnosis for cervical intraepithelial neoplasia (CIN). The technology that we created is called ZedScan™ and it is a unique adjunct diagnostic device which uses EIS (Electrical Impedance Spectroscopy) technology to identify cell changes that cannot always be seen with standard colposcopy.
What do you think makes this company unique?
The company and the technology is completely unique and born from a desire to create a device that saves people’s lives. EIS (Electrical Impedance Spectroscopy) has fantastic potential for many other uses for other diagnostics and we believe it could be crucial as the basis for more development so watch this space!
More from Interviews
- Get To Know Taiwo Akinropo, Founder And CEO At Heyfood And MENA40 Judge
- A Chat With Obinna Umeh, Co-Founder And CEO of Growwr And MENA40 2026 Judge
- We Spoke To Furkat Kasimov, Tech Entrepreneur, Venture Studio Founder And MENA40 2026 Judge About The Future Of Tech In The Middle East And North Africa
- Interview With Andrew Henderson, Chief Technology Officer At OneAdvanced On Embedding AI Into Workflows
- A Conversation With Nakul Kothari, Head of APAC And Middle East At Juspay On Payment Orchestration
- A Chat With Igor Kulatov, Co-Founder And CTO Of Aurora Borealis: Five Years Running Autonomous B2B Commerce In Production
- Interview with Ebenezer Ojo, Co-Founder At Taxmingo And MENA40 Judge
- A Chat With Kevin Weiss, CEO Of Sectigo On How The World’s Leading Certificate Authority (CA) Is Changing Into A Comprehensive Digital Trust Powerhouse
How has the company evolved over the last couple of years?
We have had a phenomenal period of growth that sees us now being used in many NHS Trusts in the UK and around the world. We just address the World Health Organisation (WHO) to discuss how the technology may help third world countries where screening programmes are not yet as advanced as the UK. Most excitingly we just received our most robust research.
Scientists looked at the examinations of 5257 women by 82 colposcopists in 26 clinics in 9 different countries. The biggest increase was in women referred with low grade changes, often the most challenging to visualise, where ZedScan had over a 50% increase in high grade disease detection. Overall it showed that Zedscan increases cervical cancer detection by 24% overall. We are delighted with this especially in the diagnosis of hard to spot cases. We are genuinely making a difference.
What can we hope to see from Zilico in the future?
We have extremely exciting plans in place for further growth, and the development of new products and enhancements to ZedScan. We really hope that we’ll be able to access people around the world who need our help. Watch out for more products that feature EIS because it is a fascinating piece of technology with great potential.
